Loading...
XSTO
IMMU
Market cap36mUSD
, Last price  
SEK
Name

Mendus AB (publ)

Chart & performance

D1W1MN
XSTO:IMMU chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
-8.80%
Rev. gr., 5y
-21.25%
Revenues
0
005,000000000016,670,00006,0002,995,00028,487,00000
Net income
-113m
L-11.79%
-2,287,294-2,670,303-2,629,325-6,887,974-16,175,036-35,614,623-43,922,885-73,587,834-80,337,643-97,860,000-135,708,000-92,469,000-136,694,000-136,991,000-101,619,000-128,399,000-113,258,000
CFO
-82m
L+2.34%
-1,666,198-3,233,502-7,146,028-9,280,851-40,102,127-40,228,602-33,738,195-46,446,815-104,670,000-145,808,000-56,626,000-138,033,000-109,331,000-162,761,000-79,671,000-81,532,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.

Key people

Alex Karlsson-Parra
Acting Chief Executive Officer · since 2019
Michaela Gertz
Chief Financial Officer · since 2018
Peter Suenaert
Chief Medical Officer · since 2016
Steven Glazer
Independent Director · since 2016
Magnus Persson
Independent Director · since 2015
URL
https://mendus.com/
IPO date
Apr 22, 2013
Employees
30
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Västra Trädgårdsgatan 15
Stockholm, AB 111 53
SE
Address
Vastra Tradgardsgatan 15
Stockholm, AB 111 53
SE
Previous name
Immunicum AB
Previous name
IMMUNICUM AKTIEBOLAG

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT